Taipei City – 
today that it priced its initial public offering of $90 million, consisting of 9,000,000
units at $10.00 per unit. The units will be listed on the Nasdaq Global Market
(“Nasdaq”) and will begin trading tomorrow, Friday, October 8th,
2021, under the ticker symbol “JMACU”. Each unit consists of one share of the
Company’s Class A common stock and one redeemable warrant entitling the holder
thereof to purchase one share of Class A common stock at a price of $11.50 per
share. Only whole warrants are exercisable. Once the securities comprising the
units begin separate trading, the shares of Class A common stock and warrants
are expected to be listed on Nasdaq under the symbols “JMAC” and “JMACW,”
respectively.
The
Company is a blank check company formed for the purpose of effecting a merger,
capital stock exchange, asset acquisition, stock purchase, reorganization or
similar business combination with one or more businesses. While the Company may
pursue an initial business combination target in any business or industry, it intends
to focus on industries that complement its management team’s background and to
capitalize on the ability of the management team to identify and acquire a
business where the management team has extensive experience. Sectors the Company
plans on exploring include, but are not limited to, the healthcare and
technology industries, specifically within the biotechnology and pharmaceutical
sectors.
The Company
is sponsored by an affiliate of Maxpro Ventures Ltd., a respected Taiwan based
venture capital firm specialized in the healthcare industry.
EF
Hutton, division of Benchmark Investments, LLC, is acting as sole book running
manager for the offering. The Company has granted the underwriter a 45-day
option to purchase up to an additional 1,350,000 units at the initial public
offering price to cover over-allotments, if any.
The
offering is being made only by means of a prospectus. Copies of the prospectus
may be obtained, when available, from EF Hutton, division of Benchmark
Investments LLC, Attn: Syndicate Department, 590 Madison Ave., 39th Floor, New
York, New York 10022, by telephone at (212) 404-7002, by fax at (646) 861-4697,
or by email at syndicate@efhuttongroup.com.
A
registration statement relating to these securities has been filed with, and
declared effective by, the Securities and Exchange Commission on October 7,
2021. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
FORWARD-LOOKING
STATEMENTS
This
press release contains statements that constitute “forward-looking statements,”
including with respect to the initial public offering and the anticipated use
of the net proceeds. No assurance can be given that the offering discussed
above will be completed on the terms described, or at all, or that the net
proceeds of the offering will be used as indicated. Forward-looking statements
are subject to numerous conditions, many of which are beyond the control of the
Company, including those set forth in the Risk Factors section of the Company’s
registration statement and preliminary prospectus for the offering filed with
the Securities and Exchange Commission (“SEC”). Copies are available on the
SEC’s website, www.sec.gov. The Company undertakes no obligation to update
these statements for revisions or changes after the date of this release,
except as required by law.
Contact
Maxpro Capital
Acquisition Corp.
5/F-4, No. 89
Songren Road, Xinyi District
Taipei City 11073
Attn: Moses Chen
Chief Executive Officer
m.chen@maxproventures.com
+886 2 7713
7952